Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. (Q38406519)

2 September 2017

Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. (English)

1 reference

2 September 2017

7

Carl D Langefeld

1 reference

2 September 2017

2

Miranda C Marion

1 reference

2 September 2017

6

Ahmed Kissebah

1 reference

2 September 2017

Samer Gawrieh

1

1 reference

2 September 2017

Richard Komorowski

3

1 reference

2 September 2017

James Wallace

4

1 reference

2 September 2017

Michael Charlton

5

1 reference

2 September 2017

Michael Olivier

8

1 reference

2 September 2017

9 December 2011

1 reference

Digestive Diseases and Sciences

2 September 2017

1 reference

2 September 2017

57

1 reference

2 September 2017

4

1 reference

2 September 2017

952-957

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-011-1994-2

2 September 2017

0 references

cites work

The epidemiology of nonalcoholic fatty liver disease: a global perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Mechanisms of disease progression in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Abnormalities of lipid metabolism in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Interaction between PPARgamma2 variants and gender on the modulation of body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1994-2

Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes

21 January 2018

1 reference

12 December 2020

Pathology of nonalcoholic fatty liver disease

1 reference

12 December 2020

Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?

1 reference

12 December 2020

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

12 December 2020

Molecular mediators of hepatic steatosis and liver injury

1 reference

12 December 2020

10.1007/S10620-011-1994-2

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

0 references

1 reference